Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Cipla
Federal Trade Commission
QuintilesIMS
Fish and Richardson
Moodys
Accenture
Baxter
Medtronic
Queensland Health

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Sulfonylurea-glitazone combinations for diabetes
Abstract:Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating diabetes mellitus and improving glycemic control.
Inventor(s): Whitcomb; Randall Wayne (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:08/970,057
Patent Claims: 1. A composition comprising from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent and from about 100 mg to about 1000 mg of a glitazone antidiabetic agent, said amounts of sulfonylurea and glitazone being synergistic for the treatment of non-insulin dependent diabetes mellitus in humans.

2. A composition of claim 1 wherein the sulfonylurea is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyhexamide, phenbutamide, and tolcyclamide.

3. A composition of claim 2 wherein the glitazone is selected from troglitazone, ciglitazone, pioglitazone, englitazone, TA 174, and BRL 49653.

4. A composition of claim 3 comprising troglitazone and glyburide.

5. A method of treating non-insulin dependent diabetes mellitus in humans comprising administering to a patient in need of treatment from about 3 mg to about 250 mg of a sulfonylurea antidiabetic agent in combination with about 100 mg to about 1000 mg of a glitazone antidiabetic agent, wherein said amounts are synergistic in the treatment of non-insulin dependent diabetes mellitus.

6. A method according to claim 5 wherein the sulfonylurea antidiabetic agent is selected from glisoxepid, glyburide, acetohexamide, chlorpropamide, glibornuride, tolbutamide, tolazamide, glipizide, gliclozide, gliquidone, glyhexamide, phenbentamide, and tolcyclamide.

7. A method according to claim 6 wherein the glitazone antidiabetic agent is selected from troglitazone, ciglitazone, pioglitazone, englitazone, TA 174, and BRL 49653.

8. A method according to claim 7 comprising a combination of glyburide and troglitazone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Dow
US Department of Justice
Argus Health
Harvard Business School
McKinsey
Mallinckrodt
Farmers Insurance
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot